Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 10:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 428 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Contraceptive Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Levonorgestrel Contraceptive Intrauterine Systems (LCS) Pearl Index Study

NCT00528112
View directory record Official record
Conditions
Contraception
Interventions
LCS12, LCS16
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
2,885 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
57
States / cities
Mobile, Alabama • Glendale, Arizona • Phoenix, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2017 · Synced Oct 17, 2026, 10:33 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Disparities in Emergency Contraceptive Metabolism Dictate Efficacy

NCT05674513
View directory record Official record
Conditions
Contraceptive Usage
Interventions
Ulipristal acetate
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 17, 2026, 10:33 PM EDT
Completed Phase 1 Interventional Results available

A Study of Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists

NCT01209143
View directory record Official record
Conditions
Solid Cancers
Interventions
Vismodegib, Rosiglitazone, Norethindrone/ethinyl estradiol
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
3
States / cities
Stanford, California • Detroit, Michigan • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 29, 2015 · Synced Oct 17, 2026, 10:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of BMS-986195 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Patients

NCT03262740
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
BMS-986195, Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 μg ethinyl estradiol)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
2
States / cities
South Miami, Florida • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 20, 2020 · Synced Oct 17, 2026, 10:33 PM EDT
Completed Not applicable Interventional Results available

Use of Norethindrone Acetate for Management of Bleeding Associated With the Etonogestrel Contraceptive Implant

NCT02353247
View directory record Official record
Conditions
Etonogestrel Contraceptive Implant, Bothersome Bleeding
Interventions
Norethindrone acetate
Drug
Lead sponsor
Norton Healthcare
Other
Eligibility
Female only
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Oct 17, 2026, 10:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Oral Contraceptives and Subantimicrobial Doxycycline: Effect on Endometrial Matrix Metalloproteinases

NCT01469585
View directory record Official record
Conditions
Breakthrough Bleeding
Interventions
Doxycycline
Drug
Lead sponsor
University of Hawaii
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 17, 2026, 10:33 PM EDT
Recruiting No phase listed Observational

Validation of Effectiveness on NaturalCycles Users

NCT07566793
View directory record Official record
Conditions
Contraception
Interventions
Log daily intercourse information, Natural Cycles application
Behavioral · Device
Lead sponsor
Natural Cycles
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 17, 2026, 10:33 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Essure Transvaginal Ultrasound (TVU) Study

NCT01327105
View directory record Official record
Conditions
Contraceptive Usage
Interventions
TVU
Device
Lead sponsor
Bayer
Industry
Eligibility
21 Years to 44 Years · Female only
Enrollment
547 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2023
U.S. locations
13
States / cities
Chandler, Arizona • Glendale, Arizona • Phoenix, Arizona + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2023 · Synced Oct 17, 2026, 10:33 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Evaluate Safety and Efficacy of an OC Preparation vs Placebo for 6 Treatment Cycles in Women With Moderate Acne.

NCT00651469
View directory record Official record
Conditions
Acne Vulgaris
Interventions
YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
14 Years to 45 Years · Female only
Enrollment
534 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2004
U.S. locations
27
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2014 · Synced Oct 17, 2026, 10:33 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Pharmacokinetic and Pharmacodynamic Study of Cyclofem

NCT01699022
View directory record Official record
Conditions
Contraception
Interventions
Injection Cyclofem
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Oct 17, 2026, 10:33 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Desogestrel-containing COCP Pharmacokinetic Validation Study

NCT05002738
View directory record Official record
Conditions
Contraception
Interventions
Desogestrel and Ethinyl Estradiol Tablets
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 30, 2025 · Synced Oct 17, 2026, 10:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levonorgestrel Drug Levels in Healthy Adult Female Participants

NCT07502417
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Ethinyl Estradiol + Levonorgestrel, ABBV-722
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 17, 2026, 10:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Evacetrapib in Healthy Female Participants

NCT01746732
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Ortho-Cyclen, Evacetrapib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 9, 2018 · Synced Oct 17, 2026, 10:33 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Clinical Use of a Contraceptive Decision Aid and Patient Outcomes

NCT05973071
View directory record Official record
Conditions
Contraceptive Usage
Interventions
Tuune Supplemented Contraceptive Visit, Traditional Contraceptive Visit
Behavioral
Lead sponsor
Texas Christian University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2023 · Synced Oct 17, 2026, 10:33 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Helping People With Health Conditions Make Birth Control Decisions

NCT03153644
View directory record Official record
Conditions
Contraception, Chronic Disease
Interventions
Interview, Observation
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Oct 17, 2026, 10:33 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy and Safety Study for an Oral Contraceptive Containing Folate

NCT00468481
View directory record Official record
Conditions
Neural Tube Defects, Contraception, Oral Contraceptives (OC)
Interventions
Drospirenone/Ethinylestradiol/Methyltetrahydrofolate, Drospirenone/Ethinylestradiol (Yaz)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
385 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
9
States / cities
Anaheim, California • San Diego, California • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2014 · Synced Oct 17, 2026, 10:33 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Effects of Continuous Administration of a Monophasic Oral Contraceptive on Bleeding Days and Endometrial and Ovarian Function

NCT00128726
View directory record Official record
Conditions
Menstrual Cycle, Healthy
Interventions
Not listed
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2006
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 21, 2012 · Synced Oct 17, 2026, 10:33 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immediate Versus Delayed Insertion of Implanon in Postpartum Adolescents

NCT03585504
View directory record Official record
Conditions
Contraceptive Usage
Interventions
Etonogestrel contraceptive implant
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
15 Years to 21 Years · Female only
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 4, 2018 · Synced Oct 17, 2026, 10:33 PM EDT
Completed Not applicable Interventional

Evaluation of an Intervention to Increase Post-abortion LARC Uptake.

NCT03214848
View directory record Official record
Conditions
Post Abortion Contraception
Interventions
Contraceptive education prior to abortion
Behavioral
Lead sponsor
Emory University
Other
Eligibility
16 Years and older · Female only
Enrollment
1,314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 20, 2018 · Synced Oct 17, 2026, 10:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Hormonal Contraception and Vaginal Health

NCT00612508
View directory record Official record
Conditions
Contraceptive Usage, Vaginal Epithelial Disruption
Interventions
Desogen (ethinyl estradiol and desogestrel), NuvaRing (ethinyl estradiol and etonogestrel)
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 8, 2012 · Synced Oct 17, 2026, 10:33 PM EDT
Completed No phase listed Observational Results available

Patient Factors Associated With Fragmentation of Copper Intrauterine Device (IUD) Requiring Hysteroscopic Removal

NCT07351084
View directory record Official record
Conditions
Intrauterine Device Complications, Contraceptive Device Failure, IUD Fragmentation, Retained Intrauterine Device, Female Contraception, Women's Health, Reproductive Health
Interventions
Not listed
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
44 participants
Timeline
2025
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 17, 2026, 10:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants

NCT07190430
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
PF-08049820, Midazolam, Dabigatran Etexilate, Portia (EE and LN) or equivalent oral tablet
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 17, 2026, 10:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Effect of Suzetrigine (SUZ) on the Pharmacokinetics of Oral Contraceptives in Healthy Female Participants

NCT06820307
View directory record Official record
Conditions
Pain
Interventions
Suzetrigine, DRSP/EE, NGM/EE
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Oct 17, 2026, 10:33 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy and Safety of Two Flexible Extended Regimens of BAY86-5300 (SH T00186D) in Comparison With the Conventional Regimen of YAZ

NCT00567164
View directory record Official record
Conditions
Contraception, Ovulation Inhibition, Contraceptives, Oral
Interventions
EE20/DRSP (BAY86-5300), EE20/DRSP (YAZ, BAY86-5300)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
1,887 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
85
States / cities
Montgomery, Alabama • Chandler, Arizona • Mesa, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2014 · Synced Oct 17, 2026, 10:33 PM EDT